Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference
Liquidia (NASDAQ: LQDA) will provide a business update at the 2026 Jefferies Global Healthcare Conference in London on November 17.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Liquidia (NASDAQ: LQDA) will provide a business update at the 2026 Jefferies Global Healthcare Conference in London on November 17. CEO Dr. Roger Jeffs and Chief Operating Officer and Chief Financial Officer Michael Kaseta will participate in a fireside chat at 10 a.m. ET/3 p.m. BT. Access will be available through Liquidia’s investor website, with a webcast replay archived for at least 30 days.
Details
Market move: LQDA +6.96% vs previous close. Jefferies conference presentation
On Nov 10, the day this news came out, the latest delayed price for LQDA is 6.96% above the previous close. Our momentum scanner has recorded 30 alerts for this stock so far that day. The latest delayed price is $51.20.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MORRISVILLE, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that Dr. Roger Jeffs, Chief Executive Officer, and Michael Kaseta, Chief Operating Officer and Chief Financial Officer, will provide an update on the company’s business in a fireside chat at the 2026 Jefferies Global Healthcare Conference, Tuesday, November 17, at 10 a.m. ET/3 p.m. BT in London.
Access to these events will be available on the “Investors” page of Liquidia’s website at https://liquidia.com/investors/events-and-presentations. A replay of the webcast will be archived on the Company's website for at least 30 days.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of YUTREPIA® (treprostinil) inhalation powder, approved for the treatment of pulmonary arterial hypertension (PAH), and in development for Raynaud’s phenomenon secondary to systemic sclerosis (SSc-RP). The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice daily via a next-generation nebulizer to treat PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD). To learn more about Liquidia, please visit www.liquidia.com.
Contact Information
Investors:
Jason Adair
Chief Business Officer
919.328.4350
Jason.adair@liquidia.com
Media:
media@liquidia.com
